In a systematic review and meta-analysis of the prevalence of HRD in both somatic and germline contexts among patients with pancreatic cancer, HRD descriptions based on genomic scarring and surrogate markers such as point mutational and structural variants were well-characterized with HR-related genes such as BRCA1, BRCA2, PALB2, ATM, ATR, CHEK2, RAD51, and the FANC genes [91]. This evidence concerns the gene CHEK2 and familial pancreatic carcinoma.